Invitris

Creating new protein-based drugs at scale

Y CombinatorWinter 2023ActiveHealthcareDrug Discovery and DeliveryBiotechNanotechnologyDrug discovery

What they do

Problem

Developing novel biological drugs, including therapies for antibiotic-resistant infections, is slow and expensive to create and scale.

Solution

A patent-pending platform that converts DNA into synthetic proteins, enabling dramatically faster and cheaper protein-drug discovery and production (including synthetic bacteriophages).

Who it's for

Biopharma companies and biomedical researchers developing new protein-based therapeutics, including phage-based anti-infective drugs.

Founders

Patrick Grossmann

Founder

My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.

Kilian Vogele

Founder

Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.